Karolinska Development announces Chairman Bo Jesper Hansen and CEO Jim Van heusden's decision to Step Down, and the promotion of Viktor Drvota to CEO
(Thomson Reuters ONE) -
STOCKHOLM - APRIL 20, 2017.
Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that Bo Jesper
Hansen, MD, PhD, Chairman of the Company's Board, has informed Karolinska
Development's Nomination Committee that he will not stand for re-election at the
2017 Annual General Meeting. The Nomination Committee's proposals will be
announced in a separate press release in connection with the notice of the 2017
Annual General Meeting which is due to take place on 24 May 2017.
Bo Jesper Hansen was appointed as Chairman in 2013. Under his chairmanship, he
initiated the successful transformation of Karolinska Development from a wide-
ranging collection of early stage science-driven projects into a highly focused
investment company with a portfolio of business-driven companies capable of
delivering significant shareholder value.
"Bo Jesper Hansen's broad industry and leadership experience has been crucial in
guiding Karolinska Development through the most significant changes in the
Company's history. We would like to thank him for his considerable efforts that
have created a strong platform for Karolinska Development's future success."
said Niclas Adler, chairman of the Nomination Committee of Karolinska
Development.
Karolinska Development also announces that its CEO, Jim Van heusden, PhD, has
tendered his resignation and will formally leave the Company at the end of
October 2017.
"Jim Van heusden has done a remarkable job as the CEO of Karolinska
Development. Under his leadership, he successfully executed a major strategic
turn-around that has positioned the Company to become a leading Nordic life
science investment company. Karolinska Development is now in an excellent
shape, with its portfolio companies poised to deliver significant value
generating milestones in the coming 12 - 18 months. With the strategic turn-
around now complete we understand Jim's desire to look for new opportunities and
wish him every success for the future," said Bo Jesper Hansen, Chairman of the
Board of Karolinska Development.
"I would like to thank Bo Jesper Hansen and the Board for their unwavering
support during the major strategic turn-around that we have implemented in the
last two years. With these changes now finished I believe it is the appropriate
time for me to look for a new challenge. I am very proud of what we have
achieved together and am convinced Karolinska Development is now in a much
stronger position to deliver value for all its stakeholders from its portfolio
of exciting therapeutic and med-tech companies." says Jim Van heusden, CEO of
Karolinska Development.
The Board of Directors is pleased to announce the promotion of Viktor Drvota MD
PhD as the Company's Chief Executive Officer, effective June 1 2017. Dr Drvota
is currently Karolinska Development's Deputy Chief Executive Officer and Chief
Investment Officer.
Bo Jesper Hansen, Chairman of the Board of Karolinska Development says: "I am
extremely pleased to announce Viktor's promotion to the role of CEO. Since
joining the Company in early 2016, Viktor has made an important contribution to
the strategic turnaround that we have implemented. With his significant life
sciences investment experience, centered on the Nordic region, and his
impressive track record, Viktor is the ideal person to lead Karolinska
Development through the next phase of its development."
Dr Drvota joined Karolinska Development as Chief Investment Officer in February
2016 and was promoted Deputy Chief Executive Officer in March 2017. Dr Drvota
brings more than 15 years of life science investment experience. Prior to
joining Karolinska Development he worked at SEB Venture Capital, where he was
Head of Life Science from 2002 and a senior investment manager. Before joining
SEB, Viktor was a practicing cardiologist at Huddinge University Hospital in
Stockholm. He has been an Associate Professor in Cardiology at Karolinska
Institutet, Stockholm, since 2002.
Dr Drvota says: "I am thrilled to take on the role of CEO in addition to my
current position as Chief Investment Officer. With the Company's strategic
turnaround now complete, Karolinska Development is in excellent shape to deliver
significant shareholder value as its portfolio companies deliver a number of
important clinical and commercial milestones over the next 12 to 18 months."
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden(at)karolinskadevelopment.com
Viktor Drvota, Chief Investment Officer and Deputy CEO, Karolinska Development
AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota(at)karolinskadevelopment.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev(at)citigatedr.co.uk
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a
proven track record as company builders and with access to a strong global
network.
For more information, please visit www.karolinskadevelopment.com
This information is information that Karolinska Development AB (publ) (Nasdaq
Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through the agency of
Jim Van heusden, at 08:00 am CEST on 20 April 2017.
Karolinska Development new CEO (ENG):
http://hugin.info/143071/R/2096933/793551.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2017 - 08:03 Uhr
Sprache: Deutsch
News-ID 537223
Anzahl Zeichen: 7866
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development announces Chairman Bo Jesper Hansen and CEO Jim Van heusden's decision to Step Down, and the promotion of Viktor Drvota to CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
